

Patient Safety ALERT – New Oral Anticoagulants

Apixaban (Eliquis®)



Dabigatranetexilate (Pradaxa®)



Rivaroxaban (Xarelto®)



Apixaban, dabigatran and rivaroxaban are new oral anticoagulants which may be prescribed for certain indications, including:

Atrial fibrillation (AF)

Venous Thromboembolism (VTE) treatment or prophylaxis

Patients should not be prescribed other anticoagulant medication (such as warfarin, dalteparin, enoxaparin, tinzaparin or heparin) if apixaban, dabigatran or rivaroxaban have been prescribed, due to an increased risk of bleeding.

There is no specific reversal agent for these new anticoagulants

FOR ACTION:

Ensure that ALL STAFF are aware of this when prescribing, administering or reviewing patients' medication.